Sanofi, a healthcare company, engages in the research, development, manufacture, and marketing of therapeutic solutions in the United States, Europe, and internationally. The company provides immunology and inflammation, rare diseases, neurology, oncology, and other medicines and vaccines. It also offers poliomyelitis, pertussis, and haemophilus influenzae type b (Hib) pediatric vaccines; respiratory syncytial virus protection and hexavalent combination vaccines protecting against diphtheria, tetanus, pertussis, polio, Hib, and hepatitis B; influenza, booster, meningitis, and travel and endemic vaccines, which includes hepatitis A, typhoid, yellow fever, and rabies vaccines. In addition, the company has a collaboration and license agreement with Exscientia to develop up to 15 novel small-molecule for oncology and immunology; ABL Bio, Inc. to develop ABL301, a treatment for alpha-synucleinopathies; Innate Pharma SA for a natural killer cell engager program targeting B7-H3; and Blackstone Life Sciences to develop pivotal studies and clinical development program. Further, it has a collaboration agreement with IGM Biosciences, Inc. to develop, manufacture, and commercialize IgM antibody; Kymera Therapeutics, Inc. to develop and commercialize protein degrader therapies targeting IRAK4 in patients with immune-inflammatory diseases; Nurix Therapeutics, Inc. to develop novel targeted protein degradation therapies; Denali Therapeutics Inc. to treat a range of systemic inflammatory diseases, such as ulcerative colitis; and Adagene Inc. for the discovery and development of antibody-based therapies. Additionally, it has a collaboration with Scribe Therapeutics Inc. to develop genome editing technologies; and co-promotion service agreement with Provention Bio, Inc. for the commercialization of teplizumab. The company was formerly known as Sanofi-Aventis and changed its name to Sanofi in May 2011. Sanofi was incorporated in 1994 and is headquartered in Paris, France.

Sanofi

Polestar Automotive Holding UK PLC Sponsored ADR Class C ( ($PSNYW) ) has issued an announcement. Polestar reported its financial and operational r...

Polestar Narrows Net Loss but Sees Revenue Dip in First-Half 2026 Results

In a report released yesterday, from CICC maintained a Buy rating on Sany Heavy Equipment International Holdings Co, with a price target of HK$14.1...

CICC Remains a Buy on Sany Heavy Equipment International Holdings Co (SNYYF)

In a report released yesterday, from CLSA maintained a Buy rating on Sany Heavy Equipment International Holdings Co, with a price target of HK$12.0...

Sany Heavy Equipment International Holdings Co (SNYYF) Gets a Buy from CLSA

Sanofi SA ($SNY) announced an update on their ongoing clinical study. The study, officially titled “An Extension Study to Evaluate the Long-term Sa...

Sanofi Extends Lunsekimig COPD Program With Long-Term Safety Study

There’s a lot to be optimistic about in the Industrial Goods sector as 2 analysts just weighed in on Dycom (DY) and Sany Heavy Equipment Internatio...

Analysts Are Bullish on Top Industrial Goods Stocks: Dycom (DY), Sany Heavy Equipment International Holdings Co (SNYYF)

Regeneron Pharmaceuticals ($REGN), Sanofi ($SNYNF) announced an update on their ongoing clinical study. The study titled “A Randomized, Double-blin...

Regeneron and Sanofi Advance IL-33 Strategy With Completed Rhinosinusitis Trial

Deutsche Bank analyst Emmanuel Papadakis maintained a Buy rating on Sanofi today and set a price target of €95.00. According to TipRanks, Papadakis...

Deutsche Bank  Reaffirms Their Buy Rating on Sanofi (SNYNF)

Sanofi SA ($SNY) announced an update on their ongoing clinical study. The study, officially titled “A Phase 1/2, Open-Label, Dose-Escalation, Dose-...

Sanofi and Blueprint Advance First-in-Human Pan-KRAS Cancer Trial, Eyeing New Oncology Upside

Sanofi SA ($SNY) announced an update on their ongoing clinical study. Sanofi SA (SNY) is launching a Phase 1/2 study called “A Phase 1/2, Parallel,...

Sanofi’s New H5N8 Flu Vaccine Trial Signals Long-Term Pandemic Preparedness Play

Synergy CHC ( ($SNYR) ) has issued an announcement. On August 20, 2026, Synergy CHC Corp. received a notice from Nasdaq stating the company is not ...

Synergy CHC Faces Nasdaq Non-Compliance Over Delayed 10-Q

Sanofi ( ($FR:SAN) ) has issued an announcement. Sanofi has reported updated figures for its share capital structure as of July 31, 2026, disclosin...

Sanofi Updates Share Capital and Voting Rights as of July 31, 2026

In a report released today, Fernando Garcia from RBC Capital maintained a Buy rating on Naturgy Energy Group, S.A., with a price target of €32.00. ...

	A	B	C	D
1	Symbol	Price	Change	Volume
2	SNY	$44.24	-0.20%	1.69M
3
4
5

	A	B	C	D
1	Symbol	Price	Change	Vol
2	SNY	$44.24	-0.2%	1.69M
3
4
5
6

SNY

Get Sanofi Data in Excel

Get Sanofi Data in Excel